Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average […]
More Stories
Main Street Capital Co. (MAIN) to Issue Dividend of $0.30 on September 27th
Main Street Capital Co. (NYSE:MAIN – Get Free Report) declared a dividend on Thursday, September 19th, investing.com reports. Shareholders of...
ReShape Lifesciences Stock Set to Reverse Split on Monday, September 23rd (NASDAQ:RSLS)
ReShape Lifesciences Inc. (NASDAQ:RSLS – Free Report) shares are scheduled to reverse split on the morning of Monday, September 23rd....
Shoe Carnival, Inc. (SCVL) to Issue Quarterly Dividend of $0.14 on October 21st
Shoe Carnival, Inc. (NASDAQ:SCVL – Get Free Report) declared a quarterly dividend on Tuesday, September 17th, Zacks reports. Investors of...
Shoe Carnival, Inc. (SCVL) to Issue Quarterly Dividend of $0.14 on October 21st
Shoe Carnival, Inc. (NASDAQ:SCVL – Get Free Report) declared a quarterly dividend on Tuesday, September 17th, Zacks reports. Investors of...
UN chief strongly condemns Mali terrorist attack
UN Secretary-General António Guterres has called for accountability following a “despicable” terrorist attack in Mali this week, his Spokesperson said...
Whole generation of children ‘lost’ amid ongoing Gaza war, UNICEF warns
Last October’s terror attacks by Hamas and other Palestinian armed groups on Israeli communities marked a devastating day for children,...